Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia
- PMID: 18395805
- PMCID: PMC2680493
- DOI: 10.1016/j.tins.2008.02.005
Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia
Abstract
Many risk genes interact synergistically to produce schizophrenia and many neurotransmitter interactions have been implicated. We have developed a circuit-based framework for understanding gene and neurotransmitter interactions. NMDAR hypofunction has been implicated in schizophrenia because NMDAR antagonists reproduce symptoms of the disease. One action of antagonists is to reduce the excitation of fast-spiking interneurons, resulting in disinhibition of pyramidal cells. Overactive pyramidal cells, notably those in the hippocampus, can drive a hyperdopaminergic state that produces psychosis. Additional aspects of interneuron function can be understood in this framework, as follows. (i) In animal models, NMDAR antagonists reduce parvalbumin and GAD67, as found in schizophrenia. These changes produce further disinhibition and can be viewed as the aberrant response of a homeostatic system having a faulty activity sensor (the NMDAR). (ii) Disinhibition decreases the power of gamma oscillation and might thereby produce negative and cognitive symptoms. (iii) Nicotine enhances the output of interneurons, and might thereby contribute to its therapeutic effect in schizophrenia.
Figures
Similar articles
-
Interneuron NMDA Receptor Ablation Induces Hippocampus-Prefrontal Cortex Functional Hypoconnectivity after Adolescence in a Mouse Model of Schizophrenia.J Neurosci. 2020 Apr 15;40(16):3304-3317. doi: 10.1523/JNEUROSCI.1897-19.2020. Epub 2020 Mar 23. J Neurosci. 2020. PMID: 32205341 Free PMC article.
-
Ketamine Administration During the Second Postnatal Week Alters Synaptic Properties of Fast-Spiking Interneurons in the Medial Prefrontal Cortex of Adult Mice.Cereb Cortex. 2016 Mar;26(3):1117-29. doi: 10.1093/cercor/bhu293. Epub 2014 Dec 4. Cereb Cortex. 2016. PMID: 25477370
-
Reviewing the ketamine model for schizophrenia.J Psychopharmacol. 2014 Apr;28(4):287-302. doi: 10.1177/0269881113512909. Epub 2013 Nov 20. J Psychopharmacol. 2014. PMID: 24257811 Free PMC article. Review.
-
5-HT2A receptor dysregulation in a schizophrenia relevant mouse model of NMDA receptor hypofunction.Transl Psychiatry. 2022 Apr 22;12(1):168. doi: 10.1038/s41398-022-01930-0. Transl Psychiatry. 2022. PMID: 35459266 Free PMC article.
-
Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia.Hippocampus. 2001;11(5):569-77. doi: 10.1002/hipo.1072. Hippocampus. 2001. PMID: 11732709 Review.
Cited by
-
Discovery of Dihydropyrrolo[1,2-a]pyrazin-3(4H)-one-Based Second-Generation GluN2C- and GluN2D-Selective Positive Allosteric Modulators (PAMs) of the N-Methyl-d-Aspartate (NMDA) Receptor.J Med Chem. 2020 Jul 23;63(14):7569-7600. doi: 10.1021/acs.jmedchem.9b01733. Epub 2020 Jul 6. J Med Chem. 2020. PMID: 32538088 Free PMC article.
-
Gestational methylazoxymethanol exposure leads to NMDAR dysfunction in hippocampus during early development and lasting deficits in learning.Neuropsychopharmacology. 2013 Jan;38(2):328-40. doi: 10.1038/npp.2012.180. Epub 2012 Sep 12. Neuropsychopharmacology. 2013. PMID: 22968815 Free PMC article.
-
Is birth a critical period in the pathogenesis of autism spectrum disorders?Nat Rev Neurosci. 2015 Aug;16(8):498-505. doi: 10.1038/nrn3956. Epub 2015 Jul 8. Nat Rev Neurosci. 2015. PMID: 26152864 Review.
-
Ursodeoxycholic Acid in Patients With Treatment-Resistant Schizophrenia Suffering From Coronavirus Disease 2019: A Hypothesis Letter.Front Psychiatry. 2021 Apr 14;12:657316. doi: 10.3389/fpsyt.2021.657316. eCollection 2021. Front Psychiatry. 2021. PMID: 33935842 Free PMC article. No abstract available.
-
Gamma oscillation in schizophrenia.Psychiatry Investig. 2011 Dec;8(4):288-96. doi: 10.4306/pi.2011.8.4.288. Epub 2011 Dec 8. Psychiatry Investig. 2011. PMID: 22216037 Free PMC article.
References
-
- Perala J, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64:19–28. - PubMed
-
- Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005;10:40–68. - PubMed
-
- Lewis DA, Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of γ-aminobutyric acid and glutamate alterations. Arch Neurol. 2006;63:1372–1376. - PubMed
-
- Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry. 2006;39(Suppl 1):S10–S14. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 MH067999-05/MH/NIMH NIH HHS/United States
- P50 MH060450/MH/NIMH NIH HHS/United States
- MH31862/MH/NIMH NIH HHS/United States
- R01 MH070560-05/MH/NIMH NIH HHS/United States
- R01 MH070560/MH/NIMH NIH HHS/United States
- MH60450/MH/NIMH NIH HHS/United States
- R01 MH042261/MH/NIMH NIH HHS/United States
- R37 MH042261/MH/NIMH NIH HHS/United States
- MH070560/MH/NIMH NIH HHS/United States
- MH067999/MH/NIMH NIH HHS/United States
- R01 MH051290/MH/NIMH NIH HHS/United States
- R01 MH067999/MH/NIMH NIH HHS/United States
- MH42261/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
